Diabetes, Obesity and Metabolism, 1462-8902

Journal

More filtering options
  1. 2020
  2. Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden

    Sofie Persson, Pierre Johansen, Emelie Andersson, Peter Lindgren, Desirée Thielke, Brian L. Thorsted, Johan Jendle & Katarina Steen Carlsson, 2020 Apr 24, In : Diabetes, Obesity and Metabolism.

    Research output: Contribution to journalArticle

  3. Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes

    Wathik Alsalim, Olga Göransson, Andrea Tura, Giovanni Pacini, Andrea Mari & Bo Ahrén, 2020 Apr, In : Diabetes, Obesity and Metabolism. 22, 4, p. 590-598 9 p.

    Research output: Contribution to journalArticle

  4. 2019
  5. Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case–control study

    Andrea Natali, Lorenzo Nesti, Elena Venturi, Angela C. Shore, Faisel Khan, Kim Gooding, Phillip E. Gates, Helen C. Looker, Fiona Dove, Isabel Goncalves, Margaretha Persson, Jan Nilsson & The SUMMIT consortium The SUMMIT consortium, 2019 Feb, In : Diabetes, Obesity and Metabolism. 21, 2, p. 412-416

    Research output: Contribution to journalArticle

  6. Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial

    Ingrid K. Hals, Hanne Fiskvik Fleiner, Nina Reimers, Marianne C. Astor, Karin Filipsson, Zuheng Ma, Valdemar Grill & Anneli Björklund, 2019, In : Diabetes, Obesity and Metabolism. 21, 10, p. 2219-2227

    Research output: Contribution to journalArticle

  7. 2018
  8. MicroRNAs in islet hormone secretion

    Jonathan L.S. Esguerra, Mototsugu Nagao, Jones K. Ofori, Anna Wendt & Lena Eliasson, 2018 Sep 1, In : Diabetes, Obesity and Metabolism. 20, Suppl 2, p. 11-19

    Research output: Contribution to journalReview article

  9. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

    Bo Ahrén, Stephen L. Atkin, Guillaume Charpentier, Mark L. Warren, John P.H. Wilding, Sune Birch, Anders Gaarsdal Holst & Lawrence A. Leiter, 2018 Sep 1, In : Diabetes, Obesity and Metabolism. 20, 9, p. 2210-2219 10 p.

    Research output: Contribution to journalArticle

  10. Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects

    Wathik Alsalim, Olga Göransson, Richard D. Carr, Roberto Bizzotto, Andrea Tura, Giovanni Pacini, Andrea Mari & Bo Ahrén, 2018 Apr, In : Diabetes, Obesity and Metabolism. 20, 4, p. 1080-1085

    Research output: Contribution to journalArticle

  11. Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review

    Ian Pearce, Rafael Simó, Monica Lövestam-Adrian, David T. Wong & Marc Evans, 2018, In : Diabetes, Obesity and Metabolism.

    Research output: Contribution to journalReview article

  12. 2017
  13. Alain Ktorza, PhD

    Bernard Thorens, Domenico Accili, Bo Ahrén, Christian Boitard, Susumu Seino & Erol Cerasi, 2017 Sep 7, In : Diabetes, obesity & metabolism. 19, S1, p. 3-3 1 p.

    Research output: Contribution to journalDebate/Note/Editorial

  14. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial

    Daisuke Yabe, Takashi Eto, Masanari Shiramoto, Shin Irie, Kenta Murotani, Yusuke Seino, Hitoshi Kuwata, Takeshi Kurose, Susumu Seino, Bo Ahrén & Yutaka Seino, 2017, In : Diabetes, Obesity and Metabolism. 19, 3, p. 442-447

    Research output: Contribution to journalArticle

  15. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes

    David Preiss, Adem Dawed, Paul Welsh, Alison Heggie, Angus G. Jones, Jacqueline Dekker, Robert Koivula, Tue H. Hansen, Caitlin Stewart, Rury R. Holman, Paul W. Franks, Mark Walker, Ewan R. Pearson & Naveed Sattar, 2017, In : Diabetes, Obesity and Metabolism. 19, 3, p. 356-363

    Research output: Contribution to journalArticle

  16. 2016
  17. Mixed meal diminishes glucose excursion compared to glucose by several adaptive mechanisms in man.

    Wathik Alsalim, Andrea Tura, Giovanni Pacini, Bilal Omar, Roberto Bizzotto, Andrea Mari & Bo Ahrén, 2016, In : Diabetes, Obesity and Metabolism. 18, 1, p. 24-33

    Research output: Contribution to journalArticle

  18. 2015
  19. The Islet and Metabolism Keep Time

    B. Thorens, D. Accili, Bo Ahrén, E. Cerasi, S. Seino & C. Boitard, 2015, In : Diabetes, Obesity and Metabolism. 17, Suppl 1, p. 3-5

    Research output: Contribution to journalDebate/Note/Editorial

  20. 2014
  21. Pronounced Reduction Of Postprandial Glucagon By Lixisenatide: A Meta-Analysis Of Randomized Clinical Trials.

    Bo Ahrén, Jean-Francois Gautier, Rachele Berria, William Stager, Ronnie Aronson & Cliff J Bailey, 2014, In : Diabetes, Obesity and Metabolism. 16, 9, p. 861-868

    Research output: Contribution to journalArticle

  22. The mind and the belly: a glance at how the nervous system directs metabolism

    D. Accili, Bo Ahrén, C. Boitard, S. Seino, B. Thorens & E. Cerasi, 2014, In : Diabetes, Obesity and Metabolism. 16, p. 1-3

    Research output: Contribution to journalDebate/Note/Editorial

  23. 2013
  24. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

    M. Monami, Bo Ahrén, I. Dicembrini & E. Mannucci, 2013, In : Diabetes, Obesity and Metabolism. 15, 2, p. 112-120

    Research output: Contribution to journalArticle

  25. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects.

    Lena Ohlsson, Wathik Alsalim, Richard D Carr, Andrea Tura, Giovanni Pacini, Andrea Mari & Bo Ahrén, 2013, In : Diabetes, Obesity and Metabolism. 15, 6, p. 531-537

    Research output: Contribution to journalArticle

  26. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

    M. Nauck, Anders Frid, K. Hermansen, A. B. Thomsen, M. During, N. Shah, T. Tankova, I. Mitha & D. R. Matthews, 2013, In : Diabetes, Obesity and Metabolism. 15, 3, p. 204-212

    Research output: Contribution to journalArticle

  27. Shifting the paradigm of islet inflammation-good guy or bad guy?

    Bo Ahrén, D Accili, C Boitard, E Cerasi, B Thorens & S Seino, 2013, In : Diabetes, Obesity and Metabolism. 15, p. 4-9

    Research output: Contribution to journalDebate/Note/Editorial

  28. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function

    M. Alba, Bo Ahrén, S. E. Inzucchi, Y. Guan, M. Mallick, L. Xu, E. A. O'Neill, D. E. Williams-Herman, K. D. Kaufman & B. J. Goldstein, 2013, In : Diabetes, Obesity and Metabolism. 15, 12, p. 1101-1110

    Research output: Contribution to journalArticle

  29. 2012
  30. The hyperstimulated beta-cell: prelude to diabetes?

    Christian Boitard, Domenico Accili, Bo Ahrén, Erol Cerasi, Susumu Seino & Bernard Thorens, 2012, In : Diabetes, Obesity and Metabolism. 14, S3, p. iv-viii

    Research output: Contribution to journalDebate/Note/Editorial

  31. Using albumin to improve the therapeutic properties of diabetes treatments.

    Bo Ahrén & B Burke, 2012, In : Diabetes, Obesity and Metabolism. 14, p. 121-129

    Research output: Contribution to journalArticle

  32. 2011
  33. Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)

    U. Lindblad, Gunnar Lindberg, Nils-Ove Månsson, Jonas Ranstam, Maria Tyrberg, S. Jansson, K. Lindwall, Mona Svärdh, L. Kindmalm & Arne Melander, 2011, In : Diabetes, Obesity and Metabolism. 13, 2, p. 185-188

    Research output: Contribution to journalArticle

  34. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.

    Bo Ahrén, J E Foley & E Bosi, 2011, In : Diabetes, Obesity and Metabolism. 13, 3, p. 193-203

    Research output: Contribution to journalArticle

  35. Dissociated incretin hormone response to protein versus fat ingestion in obese subjects.

    Ola Lindgren, R Carr, J J Holst, C Deacon & Bo Ahrén, 2011, In : Diabetes, Obesity and Metabolism. 13, p. 863-865

    Research output: Contribution to journalArticle

  36. Editorial: Long in the shade, glucagon re-occupies centre court

    J. -C. Henquin, D. Accili, Bo Ahrén, C. Boitard, S. Seino & E. Cerasi, 2011, In : Diabetes, Obesity and Metabolism. 13, Suppl. 1, p. V-VIII

    Research output: Contribution to journalDebate/Note/Editorial

  37. Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase 4 activity in obese patients with type 2 diabetes.

    M Alam, B J Van der Schueren, Bo Ahrén, G C Wang, N J Swerdlow, S Arias, M Bose, P Gorroochurn, J Teixeira, J McGinty & B Laferrère, 2011, In : Diabetes, Obesity and Metabolism. 13, 4, p. 378-381

    Research output: Contribution to journalArticle

  38. Mechanisms of Action of the DPP-4 Inhibitor Vildagliptin in Man.

    Bo Ahrén, A. Schweizer, S. Dejager, E. B. Villhauer, B. E. Dunning & J. E. Foley, 2011, In : Diabetes, Obesity and Metabolism. 13, 9, p. 775-783

    Research output: Contribution to journalReview article

  39. The future of incretin-based therapy: novel avenues-novel targets.

    Bo Ahrén, 2011, In : Diabetes, Obesity and Metabolism. 13 Suppl 1, p. 158-166

    Research output: Contribution to journalArticle

  40. 2010
  41. A low glycaemic diet improves oral glucose tolerance but has no effect on β-cell function in C57BL/6J mice.

    Ulrika Axling, Liza Rosén, Nils Wierup, Elin Östman, Inger Björck & Cecilia Holm, 2010, In : Diabetes, Obesity and Metabolism. 12, 11, p. 976-982

    Research output: Contribution to journalArticle

  42. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

    D. R. Matthews, S. Dejager, Bo Ahrén, V. Fonseca, E. Ferrannini, A. Couturier, J. E. Foley & B. Zinman, 2010, In : Diabetes, Obesity and Metabolism. 12, 9, p. 780-789

    Research output: Contribution to journalArticle

  43. What ails the beta-cell?

    D. Accili, Bo Ahrén, C. Boitard, E. Cerasi, J. -C. Henquin & S. Seino, 2010, In : Diabetes, Obesity and Metabolism. 12, p. 1-3

    Research output: Contribution to journalDebate/Note/Editorial

  44. 2009
  45. beta-Cell research - A decade of rapid growth

    Bo Ahrén, Domenico Accili, Christian Boitard, Suad Efendic, Jean-Claude Henquin, Susumu Seino, Donald F. Steiner & Erol Cerasi, 2009, In : Diabetes, Obesity and Metabolism. 11, p. IV-IX

    Research output: Contribution to journalArticle

  46. Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery

    M. Guldstrand, Bo Ahrén, E. Naslund, J. J. Holst & U. Adamson, 2009, In : Diabetes, Obesity and Metabolism. 11, 11, p. 1027-1033

    Research output: Contribution to journalArticle

  47. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes

    S. S. Lund, L. Tarnow, A. S. Astrup, P. Hovind, P. K. Jacobsen, A. C. Alibegovic, I. Parving, L. Pietraszek, M. Frandsen, P. Rossing, H. -H. Parving & Allan Vaag, 2009, In : Diabetes, Obesity and Metabolism. 11, 10, p. 966-977

    Research output: Contribution to journalArticle

  48. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

    E. Ferrannini, V. Fonseca, B. Zinman, D. Matthews, Bo Ahrén, S. Byiers, Q. Shao & S. Dejager, 2009, In : Diabetes, Obesity and Metabolism. 11, 2, p. 157-166

    Research output: Contribution to journalArticle

  49. Functional SOCS1 polymorphisms are associated with variation in obesity in whites

    T. Gylvin, J. Ek, R. Nolsoe, A. Albrechtsen, G. Andersen, R. Bergholdt, C. Brorsson, C. H. Bang-Berthelsen, T. Hansen, A E Karlsen, N. Billestrup, K. Borch-Johnsen, T. Jorgensen, O. Pedersen, T. Mandrup-Poulsen, Jörn Nerup & Flemming Pociot, 2009, In : Diabetes, Obesity and Metabolism. 11, 3, p. 196-203

    Research output: Contribution to journalArticle

  50. Genetic basis of beta-cell dysfunction in man.

    Leif Groop & Valeriya Lyssenko, 2009, In : Diabetes, Obesity and Metabolism. 11 Suppl 4, p. 149-158

    Research output: Contribution to journalArticle

  51. Identification of T1D susceptibility genes within the MHC region by combining protein interaction networks and SNP genotyping data

    C. Brorsson, N. T. Hansen, K. Lage, R. Bergholdt, S. Brunak & Flemming Pociot, 2009, In : Diabetes, Obesity and Metabolism. 11, S1, p. 60-66

    Research output: Contribution to journalArticle

  52. Inhibitory effect of kisspeptins on insulin secretion from isolated mouse islets.

    Jenny Vikman & Bo Ahrén, 2009, In : Diabetes, Obesity and Metabolism. 11 Suppl 4, p. 197-201

    Research output: Contribution to journalArticle

  53. 2008
  54. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up

    M Alvarsson, Göran Sundkvist, I Lager, Kerstin Berntorp, E Fernqvist-Forbes, L Steen, T Örn, M A Holberg, N Kirksaether & V Grill, 2008, In : Diabetes, Obesity and Metabolism. 10, 5, p. 421-429

    Research output: Contribution to journalArticle

  55. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia

    W. A. Scherbaum, A. Schweizer, A. Mari, Peter Nilsson, G. Lalanne, S. Jauffret & J. E. Foley, 2008, In : Diabetes, Obesity and Metabolism. 10, 8, p. 675-682

    Research output: Contribution to journalArticle

  56. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

    W. A. Scherbaum, A. Schweizer, A. Mari, Peter Nilsson, G. Lalanne, Y. Wang, B. E. Dunning & J. E. Foley, 2008, In : Diabetes, Obesity and Metabolism. 10, 11, p. 1114-1124

    Research output: Contribution to journalArticle

  57. Retinopathy in subjects with impaired fasting glucose The NANSY – Eye Study, Baseline report

    Maria Tyrberg, Arne Melander, Monica Lövestam Adrian & Ulf Lindblad, 2008, In : Diabetes, Obesity and Metabolism. 10, 8, p. 646-651

    Research output: Contribution to journalArticle

  58. 2007
  59. Prediction of fat-free body mass from bioelectrical impedance among 9-to 11-year-old Swedish children

    B. M. Nielsen, Magnus Dencker, L. Ward, Christian Lindén, Ola Thorsson, Magnus Karlsson & B. L. Heitmann, 2007, In : Diabetes, Obesity and Metabolism. 9, 4, p. 521-539

    Research output: Contribution to journalArticle

  60. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial

    S. S. Lund, L. Tarnow, C. D. A. Stehouwer, C. G. Schalkwijk, M. Frandsen, U. M. Smidt, O. Pedersen, H. -H. Parving & Allan Vaag, 2007, In : Diabetes, Obesity and Metabolism. 9, 3, p. 394-407

    Research output: Contribution to journalArticle

  61. 2006
  62. 2005
  63. Islet adaptation to insulin resistance: mechanisms and implications for intervention.

    Bo Ahrén & G Pacini, 2005, In : Diabetes, Obesity and Metabolism. 7, 1, p. 2-8

    Research output: Contribution to journalReview article

  64. 2004
  65. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community.

    Carl Johan Östgren, Juan Merlo, Lennart Råstam & Ulf Lindblad, 2004, In : Diabetes, Obesity and Metabolism. 6, 5, p. 367-374

    Research output: Contribution to journalArticle

  66. 2003
  67. Metabolic disorders associated with uncontrolled hypertension.

    Erik Bøg-Hansen, Ulf Lindblad, Bo Gullberg, Arne Melander & Lennart Råstam, 2003, In : Diabetes, Obesity and Metabolism. 5, 6, p. 379-387

    Research output: Contribution to journalArticle

  68. Socio-demographic and psychosocial factors are associated with features of the metabolic syndrome. The Women's Health in the Lund Area (WHILA) study.

    Jonas Lidfeldt, P Nyberg, Christina Nerbrand, Göran Samsioe, Bengt Scherstén & Carl-David Agardh, 2003, In : Diabetes, Obesity and Metabolism. 5, 2, p. 106-112

    Research output: Contribution to journalArticle

  69. 2002
  70. Efficacy, effectiveness and safety of sulphonylurea-metformin combination therapy in patients with type 2 diabetes.

    LS. Hermann, Gunnar Lindberg, Ulf Lindblad & Arne Melander, 2002, In : Diabetes, Obesity and Metabolism. 4, 5, p. 296-304

    Research output: Contribution to journalReview article

  71. 2001
  72. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes

    A. Jönsson, Bengt Hallengren, T. Rydberg & A. Melander, 2001, In : Diabetes, Obesity and Metabolism. 3, 6, p. 403-409

    Research output: Contribution to journalArticle

  73. Impaired glucose metabolism and obesity in Swedish patients with borderline isolated systolic hypertension: Skaraborg Hypertension and Diabetes Project

    Erik Bøg-Hansen, Ulf Lindblad, J Ranstam, Arne Melander & Lennart Råstam, 2001, In : Diabetes, Obesity and Metabolism. 3, 1, p. 25-31

    Research output: Contribution to journalArticle

  74. 1999
  75. Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes: the Skaraborg Hypertension and Diabetes Project

    Carl Johan Östgren, Ulf Lindblad, Erik Bøg-Hansen, Jonas Ranstam, Arne Melander & Lennart Råstam, 1999, In : Diabetes, Obesity and Metabolism. 1, 2, p. 105-112

    Research output: Contribution to journalArticle